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Abstract
Purpose Bariatric surgery is no longer considered only as a weight loss surgery but also a way of treating obesity-related
comorbidities such as type 2 diabetes mellitus (T2DM). Short-term T2DM remissions in patients undergoing laparoscopic sleeve
gastrectomy (LSG) have been shown, but there are very few reports on the mid-term results. We aimed to assess the remission
rate of T2DM in obese patients after LSG throughout 5-year follow-up.
Materials and Methodology We performed a retrospective multicenter cohort analysis of 240 patients who underwent LSG. We
assessed the remission rate of T2DM 1 year and 5 years after surgery.
Results Forty-six percent of patients achieved T2DM remission 5 years after LSG. The remission group had better weight
loss results (median% of total weight loss 5 years after: 30.1% (22.9–37.0) vs 23.0% (13.7–30.2), p < 0.001) and were
significantly younger than the no remission group (43 (38–52) vs 52 (44–58) years, p < 0.001). Duration of T2DM was
significantly shorter (2 (1–5) vs 5 (3–10) years, p < 0.001) with less insulin requirement and less diabetes-related complications
(7.2% vs 19.8%, p < 0.001) and significantly lower median DiaRem score (4.0 (IQR 2.0–6.0) vs 12.0 (IQR 5.0–16.0), p < 0.001).
Preoperative body mass index (BMI) had no effect on remission.
Conclusions Our study suggests that diabetes remission after laparoscopic sleeve gastrectomy occurs frequently, and in the 5-
year follow-up, it may remain at the level of 46%. We identified the age of patients, duration, and severity of T2DM as factors
affecting mid-term diabetes remission. Nevertheless, further well-designed trials are needed to support our findings.
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Introduction
Obesity is a common health problem worldwide, forming a
basis for the occurrence of obesity-related diseases such as
type 2 diabetes mellitus (T2DM), hypertension, obstructive
sleep apnea syndrome, and even neoplasms [1]. In recent
years, the number of bariatric procedures has been growing
constantly because they have been proven to be safe and give
satisfactory results [2]. Bariatric surgery has been proven ben-
eficial in the treatment of both obesity itself and obesity-
related diseases [3]. Laparoscopic sleeve gastrectomy (LSG)
has one of the shortest learning curves, which together with
good weight loss results explain the fact that it is frequently
performed [2, 4]. The remission of obesity-related diseases is
now mainly considered to be the reason for the increase in
bariatric procedures, and a sole weight loss effect is no longer
the only expected result. Bariatric surgery is considered to
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modulate neural mechanisms, secretion of gastrointestinal
hormones, and entail gut microbiota alterations [5]. Many
articles have shown the benefits of short-term diabetes remis-
sion in patients undergoing LSG, but there are very few re-
ports on the mid-term results [6–8].
Aim
The aim of this study was to identify the factors affecting mid-
term T2DM remission in patients undergoing LSG. We per-
formed a multicenter study to evaluate the effects of LSG on
T2DM remission in a 5-year follow-up period.
Materials and Methods
The study was approved by the institutional review board of
the Jagiellonian University Medical College, Krakow,
Poland (No. 1072.6120.117.2019). This was a multicenter
retrospective observational study. Data from seven Polish
surgical centers were collected in a web-based database;
each of the centers performs more than 50 LSG procedures
a year. Patients were operated on between 2007 and 2014;
during this time, 362 LSG procedures were performed in
diabetic patients. The LSG technique was comparable in
participating centers; the procedure is described elsewhere
[9]. Morbidly obese patients with T2DM who underwent
LSG and completed at least a 5-year follow-up period were
included in the study. Qualification criteria for the bariatric
procedure were body mass index (BMI) equal or greater
than 40 kg/m2 or BMI equal or greater than 35 kg/m2 and
obesity-related comorbidities [10, 11]. In our analysis, we
focused on complete remission of T2DM only. Diagnosis
criteria and the status of diabetes after surgery were defined
in accordance with the definitions developed by the
American Society for Metabolic and Bariatric Surgery
(ASMBS) [12]: Complete remission (HbA1c < 6% AND
fasting blood glucose < 5.56 mmol/L AND the absence of
antidiabetic medications). Very similar definition is pro-
posed by the American Diabetes Association (ADA) [13]:
Complete remission (HbA1c < 6% AND fasting blood glu-
cose < 5.56 mmol/L AND no need for antidiabetic drugs for
at least 1 year). Unfortunately the definition proposed by
ADA cannot be applied in 1-year follow-up, because the
time criterion is impossible to fulfill. Nevertheless, in our
study in a 5-year follow-up, both definitions can be applied
uniformly. Only patients in whom both 1- and 5-year fol-
low-up was obtained were included in the study. Therefore,
from the initial number of 362 cases, almost 13% (46 pa-
tients) were lost to follow-up in 1 year from the surgery but
had available 5-year follow-up results. Additionally 21%
(76 patients) of patients were lost to follow-up at 5-year
checkup. Therefore, altogether 122 patients (33.7%) were
excluded from the analysis. DiaRem score was retrospec-
tively calculated according to Still et al. [14].
The local coordinating surgeons were responsible for
data acquisition. The following variables were recorded:
annual number of LSGs performed in each participating
center; patient characteristics including sex, age, height,
maximal body weight, preoperative weight loss, and body
weight at the time of surgery and 1 and 5 years after sur-
gery; history of smoking, duration of type 2 diabetes, and
status of diabetes one and 5 years after surgery; insulin
therapy before and 1 year and 5 years after surgery; other
than insulin type of antidiabetic treatment before and 1 year
and 5 years after surgery; diabetes-related complications
(such as nephropathy, retinopathy, neuropathy, diabetic
foot syndrome, and micro- and macroangiopathy); and
HbA1c and glycemic values before and 1 year and 5 years
after surgery.
Each coordinator at a participating center received a
password-protected form, allowing data entry. All data were
completely anonymized and did not allow patient identifica-
tion. This study did not implement any changes in patients’
surgical treatment and perioperative care protocols. For this
type of study, formal consent is not required, and informed
consent does not apply. The project was supported by the
Metabolic and Bariatric Surgery Chapter of the Association
of Polish Surgeons.
Statistical Analysis
Statistical analysis was done using StatSoft Statistica 13.5
PL (StatSoft Inc., Tulsa, OK, USA). Continuous variables
were presented as means with standard deviations (SD) or
medians with inter-quartile ranges (IQR) for skewed vari-
ables. Student’s t test for normally distributed variables and
the Mann-Whitney test for skewed variables were used to
compare the received data. Dichotomous variables were
included in Pearson’s chi-square, Yates’, and Fisher’s exact
tests, depending on the quantities of data in the subgroups.
Categorization of continuous variables was done with the
use of ROC analyses. Statistically significant cut-off points
of age, duration of T2DM, preoperative HbA1c, %WL
1 year after, HbA1c 1 year after, and %TWL 5 years after
were tested in univariate logistic regression models along
with other data to determine the factors contributing to di-
abetes remission. Then, multivariate logistic regression
model was built with the use of factors significant in uni-
variate models. No multicollinearity issue was detected in
multivariate logistic regression model (VIF < 10 for all var-
iables in the model). Results were considered statistically
significant when p values were < 0.05.
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Results
Two hundred and forty patients (107 males and 133 females)
were included in the study. Median age was 49 years (IQR
40–55), median duration of T2DM before surgery was 4 years
(IQR 2–8) (32% 2 years or less, 25% 2–5 years, 20% 5–
10 years, and 10% > 10 years; in 13% duration, T2DM is
unknown), and median preoperative BMI was 47.6 kg/m2
IQR (43.3–52.0). General characteristics of patients are pre-
sented in Table 1. Total weight loss (TWL) and metabolic
changes in patients with remission after 5 years are presented
in Table 2. Patients included were treated with insulin and/or
other than insulin type of antidiabetic treatment or with diet
only.
Out of the 240 patients in the study, diabetes remission
after 5 years was achieved by 111 patients (46.3%), including
92 patients (38.3%) who achieved complete remission 1 year
after surgery and maintained diabetes remission for 5 years
after surgery and 19 patients (7.9%) who achieved diabetes
remission 5 years after surgery. Patients’ remission status after
1 year and 5 years is presented in Table 3.
Characteristics of patients 5 years after surgery are present-
ed in Table 4. Remission patients were significantly younger
than no remission patients (p < 0.001) and had a shorter time
of duration of diabetes before surgery (p < 0.001); the number
of diabetes-related complications was significantly smaller in
the remission group (p = 0.005). Patients who achieved remis-
sion had better bariatric effect—greater median %TWL and
median %EWL—but the median preoperative BMI did not
affect diabetes remission (p = 0.814). Weight and metabolic
changes of patients with diabetes remission 5 years after the
surgery are presented in Table 5.
Full data allowing DiaRem score calculation was available
for 176 patients (73%). This was due to the fact that the status
of diabetes remission was assessed in accordance with the
guidelines by the chief surgeon when entering to the database.
An exact level of HbA1c could be entered if obtainable, but
was not obligatory. Median score for patients with diabetes
remission was significantly lower than for patients without
remission (4.0 vs 12.0, p < 0.001). Patients who achieved di-
abetes remission scored mostly 3–7 points (52%) or 0–2
points (38%). Patients who did not achieve diabetes remission
most frequently scored 13–17 points (40%), 8–12 points
(15%), and 3–7 points (22%). Specific DiaRem scores are
presented in Table 6.
Table 1 General characteristics of patients
N (%) 240
Sex (Male/Female) (%) 107/133 (45%/55%)
Median age, years (IQR) 49 (40–55)
Median maximal preoperative BMI, kg/m2 (IQR) 48.7 (43.9–54.2)
Smoking status, n (%) 51 (21.3%)
Median duration of T2DM, years (IQR) 4 (2–8)
Insulin therapy preoperatively, n (%) 71 (29.6%)
Other than insulin type of antidiabetic treatment,
n (%)
209 (87.1%)
Complications of T2DM, n (%) 33 (13.8%)
Median preoperative HbA1c, % (IQR)* 7.0 (6.2–7.8)
Median preoperative fasting glucose,
mmol/L (IQR)*
7.2 (6.1–9.2)
*The data was available only for 175 patients (73%)
Table 2 Weight and metabolic changes
Weight and metabolic changes
After 1 year After 5 years
Median BMI 1 year after, kg/m2 (IQR) 34.3
(30.8–39.1)
Median BMI 5 years after, kg/m2 (IQR) 34.2
(30.8–39.0)
Median %TWL, % (IQR) 26.2
(20.5–32.6)
Median %TWL 5 years after, % (IQR) 26.1
(17.9–34.4)
Median %EWL, % (IQR) 55.4
(43.6–70.0)
Median %EWL 5 years after, % (IQR) 55.8
(38.4–72.6)
Median HbA1c 1 year after, % (IQR) 5.8 (5.3–6.1) Median HbA1c 5 years after, % (IQR) 5.8 (5.4–6.0)
Median fasting glucose 1 year after, mmol/L (IQR) 5.5 (5.0–6.3) Median fasting glucose 5 years after, mmol/L (IQR) 5.6(5.1–6.3)
Insulin sc. 1 year after, n (%) 46 (19.2%) Insulin sc. 5 years after, n (%) 29 (12.1%)
Other than insulin type of antidiabetic treatment 1 year
after, n (%)
104 (43.3%) Other than insulin type of antidiabetic treatment 5 years
after, n (%)
101 (42.1%)






No remission after 1 year 107 (45%) 19 (8%) 126
Remission after 1 year 22 (9%) relapse 92 (38%) 114
Total 129 111 240
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Univariate logistic regression models demonstrated that
younger patients (OR 0.94, 95% CI 0.91–0.96) with shorter
median diabetes duration (OR 0.81, 95% CI 0.74–0.88) had
a higher chance of diabetes remission. Patients receiving
insulin treatment before surgery were less likely to achieve
remission (OR 0.10, 95% CI 0.04–0.21). Remission was
more likely to occur in patients with fewer diabetes com-
plications (OR 0.31, 95% CI 0.13–0.74) and lower HbA1c
(OR 0.58, 95% CI 0.44–0.77) and fasting glucose levels
(OR 0.77, 95% CI 0.67–0.88) preoperatively. After 5 years,
every 1% TWL accretion and 1% EWL accretion positively
impacted diabetes remission, with OR 1.06 (95% CI 1.03–
1.08) and OR 1.03 (95% CI 1.02–1.04), respectively. There
is an inverse correlation between DiaRem score and the
odds ratio for diabetes remission (OR: 0.32; 95% CI
0.23–0.46, p < 0.001) in univariate logistic regression
model.
The data for the multivariate logistic regression model
5 years after surgery is presented in Table 7. Calculations
demonstrated that factors such as age over 45 years, pre-
operative insulin treatment, other than insulin type of an-
tidiabetic treatment 1 year after surgery, and weight loss
percentages 5 years after surgery greater than 22.0% af-
fected the odds ratio of type 2 diabetes mellitus remission
5 years after LSG.
Discussion
This study showed that T2DM remission 5 years after LSG
can be observed in almost half of the patients. They had better
postoperative weight loss, were younger, and the duration of
T2DM was shorter with less insulin requirement and less
diabetes-related complications. We also discovered that pre-
operative BMI had no effect on the remission status.
The number of bariatric procedures performed world-
wide is constantly increasing, and recently LSG overtook
laparoscopic Roux-en-Y gastric bypass (LRYGB),
representing 46.0% and 38.2%, respectively, of all opera-
tions performed since 2014 [2]. This trend may be some-
what due to the relatively shorter learning curves and
shorter operative time as well as satisfactory clinical out-
comes. Weight loss is no longer the only indication for
bariatric surgery. Metabolic changes come hand in hand
with weight loss, and hence, the resolution of metabolic
disorders such as diabetes is possible. Knowledge of factors
promoting diabetes remission together with recognition of
both short- and mid-term outcomes of different procedures
is crucial to enable conscious decision-making [15–19].
The topic of mid-term remissions after LRYGB has already
been extensively studied [20, 21]. There are also many re-
search projects investigating short-term outcomes after
Table 4 General characteristics
of patients with diabetes
remission 5 years after the surgery
Remission No Remission p value
N (%) 111 129 n/a
Males/females, n (%) 49/62 (44%/56%) 58/71 (45%/55%) 0.899
Median age, years (IQR) 43 (38–52) 52 (44–58) < 0.001
Median preoperative BMI, kg/m2 (IQR) 48.2 (43.6–51.4) 47.3 (43.0–52.2) 0.814
Median preoperativeΔBMI, kg/m2 (IQR) 1.0 (0.0–3.0) 0.7 (0–1.8) 0.068
Smoking status, n (%) 25.0 (22.5%) 26.0 (20.2%) 0.655
Median duration of T2DM, years (IQR) 2 (1–5) 5 (3–10) < 0.001
Insulin therapy, n (%) 9.0 (8.1%) 62.0 (48.1%) < 0.001
Median amount of insulin I.U. /24 h, n (IQR) 45 (27–100) 48 (36–72) 0.881
Other than insulin type of antidiabetic treatment, n (%) 92 (82.9%) 117 (90.7%) 0.072
Complications of T2DM, n (%) 8 (7.2%) 24 (19.8%) 0.005
Table 5 Weight and metabolic
changes of patients with diabetes
remission 5 years after the surgery
Remission No remission p value
Median preoperative HbA1c, % (IQR) * 6.6 (6.2–7.0) 7.2 (6.6–8.2) < 0.001
Median preoperative fasting glucose, mmol/L (IQR)* 6.4 (5.8–7.6) 7.8 (6.6–10.0) < 0.001
Median BMI 5 years after, kg/m2 (IQR) 32.8 (30.0–36.8) 35.3 (32.1–41.3) < 0.001
Median %TWL 5 years after, % (IQR) 30.1 (22.9–37.0) 23.0 (13.7–30.2) < 0.001
Median %EWL 5 years after, % (IQR) 66.6 (47.8–76.6) 47.3 (31.4–67.0) < 0.001
Median HbA1c 5 years after, % (IQR) 5.4 (5.2–5.8) 5.9 (5.5–6.5) < 0.001
*The data was available only for 175 patients (73%)
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LSG [6, 22]. Our study is one of the first to analyze mid-
term outcomes of diabetes remission in patients undergoing
LSG.
Factors promoting T2DM remission were previously
studied using short-term follow-up data [23–26], and they
coincide with the factors identified in our research. One-
year T2DM remission rates differ between authors
(Casajoana et al., 53.3%; Stallard et al., 75%; Murphy
et al. 72%) [24–26]. Data on mid-term diabetes remission
after LSG vary significantly among the studies. Some
achieve only 12.0% [27], 19.0% [28] or 23.0% [29] remis-
sion rate. Others however reach remission rate of 61.5%
[30], 77.0% [31], or even 81.9% [32]. Recently published
network meta-analysis on diabetes remission after bariatric
surgeries shows that in the follow-up over 3 years of length
after LSG, the diabetes remission rate is on the level of
39.9% [33]. Moreover, the latest published systematic re-
view of literature shows that there is no significant differ-
ence between diabetes remission in 2- to 5-year follow-up
between RYGB and LSG (50% vs 45%, 95% CI (0.94–
1.20)) [34]. This data however is hard to interpret due to
combining 2- to 5-year follow up in one analysis—overall
5-year follow-up diabetes remission results are sparse. On
the other hand, we observed diabetes relapse in a 5-year
follow-up in 22 patients (9.2%), where recently published
study [35] estimates late relapse risk after LSG at the level
of 36%.
There are several potential explanations for this variance of
results. Differences may be caused by different trial designs
(cohort studies and RCTs), different follow-up lengths (from 2
to 5 years in various combinations), and different diabetes
remission definitions (not all authors use the ASMBS or
ADA definition; some do not mention the definition that
was used). Relatively large differences in sample size may
be also observed (majority of studies included less than 50–
70 patients) in comparison to our study. Our results regarding
mid-term diabetes remission are in line with the few previous-
ly published studies but are supported by a significantly larger
sample size.
Most, but not all, of the patients who achieved diabetes
complete remission 1 year after surgery maintained diabetes
remission in the 5-year follow-up. We observed that 22 (9%)
of all 240 patients, after achieving remission initially, had a
diabetes relapse 5 years after surgery. Similarly, 19 (8%) of all
240 patients did not achieve diabetes remission 1 year after
surgery, but in the 5-year follow-up, they proved to be diabe-
tes free. This single observation is strong proof of the need for
longer follow-up to attain reliable results.
Diabetes remission rate in our study is higher after
5 years than at 1 year after the surgery. This stays in con-
trast to other researchers’ results. We speculate that in pa-
tients who show persistent weight loss, diabetes remission
may occur after 1 year, which is in line with the results of
our study.
Table 6 DiaRem score results
DiaRem Score All (n = 176) Remission (n = 77) No remission (N = 99)
0–2 42 (24%) 29 (38%) 13 (13%)
3–7 62 (35%) 40 (52%) 22 (22%)
8–12 19 (11%) 4 (5%) 15 (15%)
13–17 44 (25%) 4 (5%) 40 (40%)
18–22 9 (5%) 0 9 (9%)
Table 7 Multivariate logistic
regression model of factors
influencing odds ratio of T2DM
remission 5 years after LSG
OR 95%CI p value
Age > 45 years 0.19 0.04–0.81 0.023
Median duration of T2DM> 4 years 1.90 0.39–9.20 0.420
Insulin therapy 0.13 0.02–0.98 0.045
Complications of T2DM 0.58 0.08–4.34 0.589
Preoperative HbA1c > 7.05% 0.61 0.13–2.82 0.525
%TWL 1 year after > 23.78% 1.25 0.32–4.89 0.744
HbA1c 1 year after > 6% 1.25 0.17–9.10 0.822
Insulin sc. 1 year after 0.13 0.01–2.40 0.163
Other than insulin type of antidiabetic treatment 1 year after 0.03 0.01–0.19 < 0.001
%TWL 5 years after > 22.0% 21.20 3.31–135.52 0.001
Category of DiaRem 0.79 0.40–1.56 0.495
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Mechanisms in which bariatric surgery influences carbohy-
drate metabolism and determines diabetes status are multifac-
torial. It is considered that bariatric surgery modulates neural
mechanisms (such as vagal afferent activation) and secretion
of gastrointestinal and islet hormones (glucagone, glucagone-
like peptide-1, peptide YY, cholecystokinin, ghrelin, and
others) [5]. These hormones together with adipokines are
suspected to be predictors of durable remission and relapse
of diabetes after a bariatric procedure [36]. Gut microbiota
are considered to be altering insulin resistance and glucose
intolerance [37, 38]. In addition, changes in gut microbiota
composition have been proven to be associated with bariatric
surgery procedures, although results are inconsistent through-
out the literature [5]. Serum bile acids levels and composition
correlate with metabolic changes after bariatric procedures as
well [39].
In our study, we decided to retrospectively calculate
DiaRem scale. It was primarily developed to assess diabetes
remission possibility after RYGB, but we wanted to check its
applicability in LSG patients. We found that DiaRem score <
8 has high predictive value of diabetes remission. In our opin-
ion, it proves that this scale can be successfully used not only
in RYGB but also in LSG patients.
This study also has some limitations. Firstly, the studied
data were partially retrospective due to the study design.
Only patients for whom full follow-up was obtained were
included in the study; therefore, 34% of potential study
participants were not included. Remaining diabetic patients
not included in the study may be the source of bias.
Secondly, relatively short duration of T2DM (57% patients
had less than 5 years of diabetes duration, and 77% had less
than 10-year T2DM history) may be affecting diabetes re-
mission results. Furthermore, it is likely that procedures
performed throughout the years varied in different centers,
and the lack of uniformity due to the ongoing learning curve
may be the source of bias. We did not analyze surgical
techniques or the postoperative course; however, it can be
assumed that 5-year follow-up allowed short-term con-
founding factors such as surgical complications to be
eliminated.
Conclusions
Our study suggests that T2DM remission after laparoscopic
sleeve gastrectomy done for severe obesity is frequent and
may affect as many as 46% of patients with preoperative dia-
betes 5 years after the surgery. We identified the age of pa-
tients, duration, and severity of type 2 diabetes as factors af-
fecting 5-year diabetes remission. Due to the lack of sufficient
research into mid-term diabetes remission, further investiga-
tion is necessary.
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